- 90.4k views
Dapagliflozin in patients with Chronic Kidney Disease
Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has shown promise in the management of Chronic Kidney Disease (CKD) in patients with type 2 diabetes. Dapagliflozin has demonstrated efficacy in reducing the progression of CKD in individuals with type 2 diabetes by inhibiting the reabsorption of glucose and sodium in the proximal renal tubules. Clinical trials have indicated that dapagliflozin reduces albuminuria, a key marker of kidney damage, thereby potentially slowing the decline in renal function. The use of dapagliflozin has been associated with improvements in glomerular filtration rate (GFR), suggesting a positive impact on overall kidney function. Dapagliflozin's mechanism of action involves promoting glycosuria and natriuresis, leading to a reduction in intraglomerular pressure and ultimately protecting the kidneys. Studies have highlighted the cardiovascular benefits of dapagliflozin in CKD patients, including a reduction in major adverse cardiovascular events and heart failure hospitalizations. Dapagliflozin's renal protective effects extend beyond glycemic control, making it a valuable therapeutic option for patients with both diabetes and CKD. The safety profile of dapagliflozin in CKD patients appears favorable, with few adverse effects reported in clinical trials. Dapagliflozin's impact on renal outcomes has prompted its inclusion in treatment guidelines for individuals with type 2 diabetes and CKD.
About the Speaker
Dr Satyanarayana Garre
Consultant Nephrologist, Apollo Hospitals, Hyderabad
Upcoming Case Discussions
Hyperlipidemia: From Diagnosis to Treatment
Hyperlipidemia is a condition characterized by elevated levels of lipids, such as cholesterol and triglycerides, in the blood, which can increase the risk of cardiovascular diseases. Diagnosis typically involves blood tests measuring lipid profiles, while treatment focuses on lifestyle changes, such as diet and exercise, alongside medications like statins to manage cholesterol levels and reduce cardiovascular risk. Regular monitoring is essential for effective management and prevention of complications.
Acne: Disorders and Treatment Approaches
Acne is a common dermatological condition caused by clogged pores, excess sebum production, bacterial growth, and inflammation. It can manifest as blackheads, whiteheads, papules, pustules, or cysts, often leading to scarring if untreated. Various factors, including hormonal changes, diet, stress, and genetics, influence its severity. Treatment approaches range from topical and oral medications, such as retinoids, antibiotics, and hormonal therapy, to advanced procedures like chemical peels and laser therapy. A personalized skincare regimen, along with lifestyle modifications, plays a crucial role in managing and preventing acne.
Pulmonary Hypertension
Safer alternatives in pain management focus on reducing the reliance on opioids and minimizing the risk of addiction or side effects. Non-opioid medications such as acetaminophen, NSAIDs, and anticonvulsants are increasingly used for managing both acute and chronic pain. Additionally, physical therapy, acupuncture, and cognitive-behavioral therapy are non-pharmacological approaches that effectively address pain without the risks associated with traditional painkillers. For certain cases, interventional procedures like nerve blocks or spinal cord stimulation offer targeted relief while minimizing systemic side effects. These alternatives aim to provide effective pain management while enhancing patient safety and quality of life.
Molecular and Genetic studies in Gynaecological Malignancies
Molecular and genetic studies in gynecological malignancies have revolutionized diagnostics, prognostics, and targeted therapies. Advances in genomic sequencing have identified key mutations in ovarian (BRCA1/2, TP53), endometrial (PTEN, MSI), and cervical cancers (HPV integration, PIK3CA). These findings aid in precision medicine, guiding individualized treatments like PARP inhibitors for BRCA-mutated ovarian cancer. Epigenetic modifications, including DNA methylation and miRNA regulation, further influence tumor progression and therapeutic response. Emerging technologies like liquid biopsies and multi-omics approaches enhance early detection and monitoring. Understanding these molecular pathways is crucial for developing novel therapies and improving survival outcomes in gynecological malignancies.
AI in Enhancing Emergency Care
AI is revolutionizing emergency care by enabling faster, more accurate decision-making. It helps triage patients efficiently, analyze medical data in real-time, and predict outcomes based on historical data, which can prioritize critical cases. AI-powered tools, like diagnostic imaging analysis and predictive algorithms, assist doctors in identifying conditions such as strokes or heart attacks earlier, improving survival rates. Additionally, AI enhances resource allocation and staff management in emergency departments, optimizing response times and reducing workload for healthcare providers.
Author Post
Impact
+
Talks
+
webinar
+
no.of registrations
One liner about speaker
Why is speaker relevant?
Dr Satyanarayana Garre's Talks on Assimilate
- 1st-December-2023, TIME : 03:00PM - 04:00PM
- 0
Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has shown promise in the management of Chronic Kidney Disease (CKD) in patients with type 2 diabetes. Dapagliflozin has demonstrated efficacy in reducing the progression of CKD in individuals with type 2 diabetes by inhibiting the reabsorption of glucose and sodium in the proximal renal tubules. Clinical trials have indicated that dapagliflozin reduces albuminuria, a key marker of kidney damage, thereby potentially slowing the decline in renal function. The use of dapagliflozin has been associated with improvements in glomerular filtration rate (GFR), suggesting a positive impact on overall kidney function. Dapagliflozin's mechanism of action involves promoting glycosuria and natriuresis, leading to a reduction in intraglomerular pressure and ultimately protecting the kidneys. Studies have highlighted the cardiovascular benefits of dapagliflozin in CKD patients, including a reduction in major adverse cardiovascular events and heart failure hospitalizations. Dapagliflozin's renal protective effects extend beyond glycemic control, making it a valuable therapeutic option for patients with both diabetes and CKD. The safety profile of dapagliflozin in CKD patients appears favorable, with few adverse effects reported in clinical trials. Dapagliflozin's impact on renal outcomes has prompted its inclusion in treatment guidelines for individuals with type 2 diabetes and CKD.
- 1st-December-2023, TIME : 03:00PM - 04:00PM
- 0
Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has shown promise in the management of Chronic Kidney Disease (CKD) in patients with type 2 diabetes. Dapagliflozin has demonstrated efficacy in reducing the progression of CKD in individuals with type 2 diabetes by inhibiting the reabsorption of glucose and sodium in the proximal renal tubules. Clinical trials have indicated that dapagliflozin reduces albuminuria, a key marker of kidney damage, thereby potentially slowing the decline in renal function. The use of dapagliflozin has been associated with improvements in glomerular filtration rate (GFR), suggesting a positive impact on overall kidney function. Dapagliflozin's mechanism of action involves promoting glycosuria and natriuresis, leading to a reduction in intraglomerular pressure and ultimately protecting the kidneys. Studies have highlighted the cardiovascular benefits of dapagliflozin in CKD patients, including a reduction in major adverse cardiovascular events and heart failure hospitalizations. Dapagliflozin's renal protective effects extend beyond glycemic control, making it a valuable therapeutic option for patients with both diabetes and CKD. The safety profile of dapagliflozin in CKD patients appears favorable, with few adverse effects reported in clinical trials. Dapagliflozin's impact on renal outcomes has prompted its inclusion in treatment guidelines for individuals with type 2 diabetes and CKD.
- 1st-December-2023, TIME : 03:00PM - 04:00PM
- 0
Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has shown promise in the management of Chronic Kidney Disease (CKD) in patients with type 2 diabetes. Dapagliflozin has demonstrated efficacy in reducing the progression of CKD in individuals with type 2 diabetes by inhibiting the reabsorption of glucose and sodium in the proximal renal tubules. Clinical trials have indicated that dapagliflozin reduces albuminuria, a key marker of kidney damage, thereby potentially slowing the decline in renal function. The use of dapagliflozin has been associated with improvements in glomerular filtration rate (GFR), suggesting a positive impact on overall kidney function. Dapagliflozin's mechanism of action involves promoting glycosuria and natriuresis, leading to a reduction in intraglomerular pressure and ultimately protecting the kidneys. Studies have highlighted the cardiovascular benefits of dapagliflozin in CKD patients, including a reduction in major adverse cardiovascular events and heart failure hospitalizations. Dapagliflozin's renal protective effects extend beyond glycemic control, making it a valuable therapeutic option for patients with both diabetes and CKD. The safety profile of dapagliflozin in CKD patients appears favorable, with few adverse effects reported in clinical trials. Dapagliflozin's impact on renal outcomes has prompted its inclusion in treatment guidelines for individuals with type 2 diabetes and CKD.
- 1st-December-2023, TIME : 03:00PM - 04:00PM
- 0
Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor that has shown promise in the management of Chronic Kidney Disease (CKD) in patients with type 2 diabetes. Dapagliflozin has demonstrated efficacy in reducing the progression of CKD in individuals with type 2 diabetes by inhibiting the reabsorption of glucose and sodium in the proximal renal tubules. Clinical trials have indicated that dapagliflozin reduces albuminuria, a key marker of kidney damage, thereby potentially slowing the decline in renal function. The use of dapagliflozin has been associated with improvements in glomerular filtration rate (GFR), suggesting a positive impact on overall kidney function. Dapagliflozin's mechanism of action involves promoting glycosuria and natriuresis, leading to a reduction in intraglomerular pressure and ultimately protecting the kidneys. Studies have highlighted the cardiovascular benefits of dapagliflozin in CKD patients, including a reduction in major adverse cardiovascular events and heart failure hospitalizations. Dapagliflozin's renal protective effects extend beyond glycemic control, making it a valuable therapeutic option for patients with both diabetes and CKD. The safety profile of dapagliflozin in CKD patients appears favorable, with few adverse effects reported in clinical trials. Dapagliflozin's impact on renal outcomes has prompted its inclusion in treatment guidelines for individuals with type 2 diabetes and CKD.